Generation of thymic epithelial progenitor cells in vitro

US9850465B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9850465-B2
Application numberUS-201414770625-A
CountryUS
Kind codeB2
Filing dateFeb 26, 2014
Priority dateFeb 27, 2013
Publication dateDec 26, 2017
Grant dateDec 26, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional TEP cells that mature into thymic epithelial cells in vivo.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for generating thymic epithelial progenitor (TEP) cells, the method comprising: culturing definitive endodermal (DE) cells, obtained from pluripotent stem cells, in a medium comprising an activator of retinoic acid receptor, an activator of bone morphogenetic protein (BMP) signaling, and an inhibitor of transforming growth factor-β (TGF-β) signaling to produce anterior foregut endodermal (AFE) cells; culturing the AFE cells in a medium comprising an activator of retinoic acid receptor, an activator of bone morphogenetic protein (BMP) signaling, and an inhibitor of transforming growth factor-β (TGF-β) signaling to produce ventral pharyngeal endodermal (VPE) cells; and culturing the VPE cells in a medium comprising an activator of retinoic acid receptor and an activator of bone morphogenetic protein (BMP) signaling to produce the TEP cells. 2. The method of claim 1 , wherein the DE cells are obtained from pluripotent stem cells by culturing pluripotent stem cells in a medium comprising a growth factor selected from the group consisting of Nodal, Activin A, and Activin B. 3. The method of claim 2 , wherein the medium for culturing the AFE cells further comprises a Wnt family member, a fibroblast growth factor (FGF), and an inhibitor of hedgehog signaling. 4. The method of claim 3 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 5. The method of claim 3 , wherein the TEP cells express FOXN1. 6. The method of claim 2 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 7. The method of claim 6 , wherein the TEP cells express FOXN1. 8. The method of claim 2 , wherein the TEP cells express FOXN1. 9. The method of claim 1 , wherein the pluripotent stem cells are selected from the group consisting of embryonic stem cell, embryonic germ cells, and induced pluripotent stem cell. 10. The method of claim 9 , wherein the pluripotent stem cells are primate pluripotent stem cells (pPS) cells. 11. The method of claim 10 , wherein the pPS cells are human pluripotent stem (hPS) cells. 12. The method of claim 11 , wherein the hPS cells are human embryonic stem (hES) cells. 13. The method of claim 11 , wherein the hPS cells are induced pluripotent stem (iPS) cells. 14. The method of claim 1 , wherein the medium for culturing the AFE cells further comprises a Wnt family member, a fibroblast growth factor (FGF), and an inhibitor of hedgehog signaling. 15. The method of claim 14 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 16. The method of claim 14 , wherein the TEP cells express FOXN1. 17. The method of claim 1 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 18. The method of claim 17 , wherein the TEP cells express FOXN1. 19. The method of claim 1 , wherein the TEP cells express FOXN1.

Assignees

Inventors

Classifications

  • Wnt; Frizzeled · CPC title

  • Hedgehog proteins; Cyclopamine (inhibitor) · CPC title

  • Activin; Inhibin; Mullerian inhibiting substance · CPC title

  • of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title

  • from embryonic cells · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9850465B2 cover?
Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional T…
Who is the assignee on this patent?
Univ California
What technology area does this patent fall under?
Primary CPC classification C12N5/065. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).